The Epoch Times An inexpensive antidepressant drug has been found to reduce the risk of hospitalization in high-risk adults recently diagnosed with COVID-19 by over 30 percent, according to a study published in The Lancet Global Health.
The study, titled, “Effect of early treatment with fluvoxamine on risk of emergency care and hospitalization among patients with COVID-19: the TOGETHER randomized, platform clinical trial,” was published on Oct. 27.
Fluvoxamine is an FDA-approved drug that belongs to a group of medicines known as serotonin reuptake inhibitors (SSRIs).
